Effect of Berberine Administration on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion

Pérez-Rubio, Karina G.; González-Ortı́z, Manuel; Martı́nez-Abundis, Esperanza; Robles-Cervantes, José Antonio; Espinel-Bermúdez, María Claudia

doi:10.1089/met.2012.0183

Cited by 99 publications

(68 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In subjects with metabolic syndrome, BBR administration induces a 36% remission of the presence of metabolic syndrome, decreases waist circumference, systolic blood pressure, TG, glucose levels and insulin secretion, and increases insulin sensitivity [107]. BBR also reduces BMI, leptin levels and leptin/adiponectin ratio (Table 4), suggesting an adjustment of adipokine profile, as indicated by the in vitro finding that treatment of pre-adipocytes with BBR inhibits the differentiation to mature adipocytes as well as leptin and adiponectin expression and secretion [108].…”

Section: Bbr In the Treatment Of Diabetes And Metabolic Syndromementioning

confidence: 99%

Berberine, a plant alkaloid with lipid- and glucose-lowering properties: From in vitro evidence to clinical studies

2015

View full text Add to dashboard Cite

Section: Bbr In the Treatment Of Diabetes And Metabolic Syndromementioning

confidence: 99%

Berberine, a plant alkaloid with lipid- and glucose-lowering properties: From in vitro evidence to clinical studies

2015

View full text Add to dashboard Cite

“…Berberine is a natural isoquinoline alkaloid, which is present in medicinal herbs Coptidis rhizome (Huanglian in Chinese). Recent clinical studies have shown that berberine reduces blood pressure and increases systemic insulin sensitivity in patients with metabolic syndrome (Perez‐Rubio et al , ). Berberine has been shown to lower blood glucose and modulate lipid metabolism by activating AMP‐activated protein kinase (AMPK) (Ko et al , ; Chang et al , ).…”

Section: Introductionmentioning

confidence: 99%

Berberine improves mesenteric artery insulin sensitivity through up‐regulating insulin receptor‐mediated signalling in diabetic rats

Geng

Xing

et al. 2016

British J Pharmacology

View full text Add to dashboard Cite

*Feng-Hao Geng and Guo-Hua Li contributed equally to this work. BACKGROUND AND PURPOSEBerberine, a small molecule derived from Coptidis rhizome, has been found to be potent at lowering blood glucose and regulating lipid metabolism. Recent clinical studies have shown that berberine reduces blood pressure and increases systemic insulin sensitivity in patients with metabolic syndrome; however, the underlying mechanism is still unclear. Here, we investigated the mechanism by which berberine improves vascular insulin sensitivity in diabetic rats. EXPERIMENTAL APPROACHDiabetes was induced in male Sprague-Dawley rats by feeding a high-fat diet and administration of a low dose of streptozotocin. These diabetic rats were treated with berberine (200 mg·kg À1 ·day À1 , gavage) for 4 weeks. Vascular dilation was determined in isolated mesenteric artery rings. Effects of berberine on insulin signalling were also studied in human artery endothelial cells cultured in high glucose (25 mmol·L À1 ) and palmitate (500 μmol·L À1 ). KEY RESULTSBerberine treatment for 4 weeks significantly restored the impaired ACh-and insulin-induced vasodilatation of mesenteric arteries from diabetic rats. In isolated mesenteric artery rings, berberine (2.5-10 μmol·L À1 ) elicited dose-dependent vasodilatation and significantly enhanced insulin-induced vasodilatation. Mechanistically, berberine up-regulated phosphorylation of the insulin receptor and its downstream signalling molecules AMPK, Akt and eNOS, and increased cell viability and autophagy in cultured endothelial cells. Moreover, down-regulating insulin receptors with specific siRNA significantly attenuated berberine-induced phosphorylation of AMPK. CONCLUSIONS AND IMPLICATIONSBerberine improves diabetic vascular insulin sensitivity and mesenteric vasodilatation by up-regulating insulin receptor-mediated signalling in diabetic rats. These findings suggest berberine has potential as a preventive or adjunctive treatment of diabetic vascular complications. LINKED ARTICLESThis article is part of a themed section on Chinese Innovation in Cardiovascular Drug Discovery. To view the other articles in this section visit http://dx

show abstract

“…Although the low bioavailability [20] limited its wide use in clinical practice, berberine is already studied in a lot of clinical studies due to its various effects including lipid-lowering [21], changing the blood concentration of cyclosporin A in renal transplanted recipients [22], improving insulin resistance in type 2 diabetes mellitus patients [23,24], and ameliorating inflammation in patients with acute coronary syndrome [25]. Several studies have reported that berberine exerts its beneficial effects in diabetic nephropathy (DN) through the suppression of OS and ERS [26,27].…”

Section: Introductionmentioning

confidence: 99%

Berberine Improved Aldo-Induced Podocyte Injury via Inhibiting Oxidative Stress and Endoplasmic Reticulum Stress Pathways both In Vivo and In Vitro

Wang¹,

Xu²,

He³

et al. 2016

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Berberine, a naturally occurring isoquinoline alkaloid, acts against oxidative stress (OS) and endoplasmic reticulum stress (ERS), both of which are responsible for Aldosterone (Aldo) -induced podocyte injury. However, the direct effects of berberine on Aldo-induced OS, ERS, and podocyte injury are not well defined. Methods: Uninephrectomized Sprague-Dawley rats were given 1% NaCl (salt) in their water and an Aldo infusion (0.75 µg/h) for 28 days to induce podocyte injury in the Aldo group. In the Aldo/berberine group, in addition to Aldo infusion, rats were administered 150 mg/kg berberine per day by gastric gavage for 4 weeks. Podocytes were incubated in media containing either buffer or Aldo in the presence or absence of berberine for variable time periods. The kidney tissues and podocytes were then investigated using morphological analysis, immunohistochemistry, transmission electron microscopy, western blot, DHE staining, DCFDA fluorescence, and Annexin V staining. Results: Here, we have reported that berberine attenuated Aldo-induced OS, ERS, and podocyte injury both in vivo and in vitro. Additionally, berberine treatment improved the extensive fusion of foot processes in electron micrographs resulting from Aldo/salt infusion in rats. Conclusion: Berberine may be examined as an effective agent against Aldo-induced podocyte injury.

show abstract

Effect of Berberine Administration on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion

Abstract: Administration of berberine leads to remission of metabolic syndrome and decreases in waist circumference, SBP, triglycerides, and total insulin secretion, with an increase in insulin sensitivity.

Cited by 99 publications

References 14 publications

Berberine, a plant alkaloid with lipid- and glucose-lowering properties: From in vitro evidence to clinical studies

Berberine, a plant alkaloid with lipid- and glucose-lowering properties: From in vitro evidence to clinical studies

Berberine improves mesenteric artery insulin sensitivity through up‐regulating insulin receptor‐mediated signalling in diabetic rats

Berberine Improved Aldo-Induced Podocyte Injury via Inhibiting Oxidative Stress and Endoplasmic Reticulum Stress Pathways both In Vivo and In Vitro

Contact Info

Product

Resources

About